BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 22365882)

  • 1. Use of SBA-15 for furosemide oral delivery enhancement.
    Ambrogi V; Perioli L; Pagano C; Marmottini F; Ricci M; Sagnella A; Rossi C
    Eur J Pharm Sci; 2012 May; 46(1-2):43-8. PubMed ID: 22365882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement of dissolution rate of piroxicam by inclusion into MCM-41 mesoporous silicate.
    Ambrogi V; Perioli L; Marmottini F; Giovagnoli S; Esposito M; Rossi C
    Eur J Pharm Sci; 2007 Nov; 32(3):216-22. PubMed ID: 17826966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modifying release of poorly soluble active pharmaceutical ingredients with the amine functionalized SBA-16 type mesoporous materials.
    Jadach B; Feliczak-Guzik A; Nowak I; Milanowski B; Piotrowska-Kempisty H; Murias M; Lulek J
    J Biomater Appl; 2019 Apr; 33(9):1214-1231. PubMed ID: 30791849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
    Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploitation of 3D face-centered cubic mesoporous silica as a carrier for a poorly water soluble drug: influence of pore size on release rate.
    Zhu W; Wan L; Zhang C; Gao Y; Zheng X; Jiang T; Wang S
    Mater Sci Eng C Mater Biol Appl; 2014 Jan; 34():78-85. PubMed ID: 24268236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New oral solid dosage form for furosemide oral administration.
    Perioli L; D'Alba G; Pagano C
    Eur J Pharm Biopharm; 2012 Apr; 80(3):621-9. PubMed ID: 22230797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanoprecipitation with sonication for enhancement of oral bioavailability of furosemide.
    Sahu BP; Das MK
    Acta Pol Pharm; 2014; 71(1):129-37. PubMed ID: 24779201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation, characterization, and evaluation in vivo of Ins-SiO₂-HP55 (insulin-loaded silica coating HP55) for oral delivery of insulin.
    Zhao X; Shan C; Zu Y; Zhang Y; Wang W; Wang K; Sui X; Li R
    Int J Pharm; 2013 Sep; 454(1):278-84. PubMed ID: 23830939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxidized mesoporous silicon microparticles for improved oral delivery of poorly soluble drugs.
    Wang F; Hui H; Barnes TJ; Barnett C; Prestidge CA
    Mol Pharm; 2010 Feb; 7(1):227-36. PubMed ID: 19874003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement of dissolution properties of furosemide by complexation with beta-cyclodextrin.
    Ozdemir N; Ordu S
    Drug Dev Ind Pharm; 1998 Jan; 24(1):19-25. PubMed ID: 15605593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ketoprofen mesoporous silica nanoparticles SBA-15 hard gelatin capsules: preparation and in vitro/in vivo characterization.
    Abd-Elrahman AA; El Nabarawi MA; Hassan DH; Taha AA
    Drug Deliv; 2016 Nov; 23(9):3387-3398. PubMed ID: 27167529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of biodegradable porous starch foam for improving oral delivery of poorly water soluble drugs.
    Wu C; Wang Z; Zhi Z; Jiang T; Zhang J; Wang S
    Int J Pharm; 2011 Jan; 403(1-2):162-9. PubMed ID: 20937370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inclusion of fenofibrate in a series of mesoporous silicas using microwave irradiation.
    Waters LJ; Hussain T; Parkes G; Hanrahan JP; Tobin JM
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):936-41. PubMed ID: 23954510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study on formulation variables of methotrexate loaded mesoporous MCM-41 nanoparticles for dissolution enhancement.
    Vadia N; Rajput S
    Eur J Pharm Sci; 2012 Jan; 45(1-2):8-18. PubMed ID: 22067974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dissolution enhancement of a model poorly water-soluble drug, atorvastatin, with ordered mesoporous silica: comparison of MSF with SBA-15 as drug carriers.
    Maleki A; Hamidi M
    Expert Opin Drug Deliv; 2016; 13(2):171-81. PubMed ID: 26636904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applications of supercritical fluids to enhance the dissolution behaviors of Furosemide by generation of microparticles and solid dispersions.
    De Zordi N; Moneghini M; Kikic I; Grassi M; Del Rio Castillo AE; Solinas D; Bolger MB
    Eur J Pharm Biopharm; 2012 May; 81(1):131-41. PubMed ID: 22266263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Supramolecular complexes of maltodextrin and furosemide polymorphs: a new approach for delivery systems.
    Garnero C; Chattah AK; Longhi M
    Carbohydr Polym; 2013 Apr; 94(1):292-300. PubMed ID: 23544541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dissolution rate of furosemide from polyethylene glycol solid dispersions.
    Ozdemir N; Ordu S
    Farmaco; 1997 Oct; 52(10):625-9. PubMed ID: 9507675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of surface area of silica particles on dissolution rate and oral bioavailability of poorly water soluble drugs: a case study with aceclofenac.
    Kumar D; Sailaja Chirravuri SV; Shastri NR
    Int J Pharm; 2014 Jan; 461(1-2):459-68. PubMed ID: 24368106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving furosemide polymorphs properties through supramolecular complexes of β-cyclodextrin.
    Garnero C; Chattah AK; Longhi M
    J Pharm Biomed Anal; 2014 Jul; 95():139-45. PubMed ID: 24667568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.